Chlorpromazine: Nursing Drug Guide, Orthostatic Hypotension & NCLEX Review
First-dose postural hypotension, extrapyramidal reactions, and fall injury can occur even when the dose looks modest—pair orthostatic vitals, EPS screening, and prescriber coordination on every pass, especially in older adults.
Chlorpromazine can cause postural hypotension, tachycardia, dizziness, and syncope—often after the first oral dose—plus somnolence and motor instability that increase fall and fracture risk. Labeling also warns of dose-related extrapyramidal symptoms (dystonia, pseudo-parkinsonism, tardive dyskinesia) and rare neuroleptic malignant syndrome (NMS). Boxed warning: elderly patients with dementia-related psychosis treated with antipsychotics have increased mortality; chlorpromazine is not approved for that use. Obtain orthostatic blood pressure before and after early doses, complete fall-risk assessment at initiation and during long-term therapy, and hold or clarify if hypotension, fever with rigidity, or acute dystonia appears.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before and after the first doses (and every titration), check orthostatic blood pressure and gait—postural hypotension can occur rarely after the first oral dose and may progress to a shock-like state. Hold the dose, position the patient safely, and notify the prescriber or pharmacist when dizziness, syncope, or a meaningful BP drop follows chlorpromazine.
Most common brand names
Chlorpromazine is a first-generation (typical) antipsychotic phenothiazine available generically and historically marketed under the brand Thorazine in the United States. Verify formulation (tablet strength, concentrate, injection) on the MAR—potency and volume differ by product.
Oral tablet strengths commonly include 10, 25, 50, 100, and 200 mg (100 mg and 200 mg tablets are labeled for severe neuropsychiatric conditions only). Concentrated oral solution and injectable hydrochloride products are available from multiple manufacturers. Chlorpromazine is a single-entity agent; always distinguish it from prochlorperazine (antiemetic phenothiazine) during verification and LASA checks.
Why we give it — Indications
Chlorpromazine is a low-potency typical antipsychotic with strong sedating and antiemetic properties. Nurses most often see it for agitation and acute behavioral disturbance, psychotic disorders, nausea/vomiting, and preoperative anxiety—settings where hypotension and oversedation can be mistaken for calming success.
| Use | Detail |
|---|---|
| Psychotic disorders / schizophrenia | Indicated for management of manifestations of psychotic disorders and treatment of schizophrenia and bipolar disorder manic episodes. Hospitalized acute states may begin with IM injection until controlled, then transition to oral therapy with gradual dosage increases per labeling. |
| Nausea, vomiting, and behavioral emergencies | Also used for nausea and vomiting (10–25 mg q4–6h PRN oral), presurgical apprehension, intractable hiccups, acute intermittent porphyria, tetanus adjunct, and short-term severe behavioral problems in children per prescribing information. Antiemetic effect may mask other conditions—do not ignore new abdominal or neurologic signs. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
The precise therapeutic mechanism is not fully known; chlorpromazine is primarily psychotropic with sedative and antiemetic activity. It acts at multiple CNS levels with strong antiadrenergic (alpha-blocking) effects, weaker peripheral anticholinergic activity, and slight antihistaminic properties. The alpha-adrenergic blockade underlies orthostatic hypotension and dizziness—the primary bedside hazard nurses must monitor on initiation and after dose increases.
Dosing overview
Adjust dosage to the individual and severity of illness; increase gradually, especially in debilitated, emaciated, or elderly patients. Oral and parenteral milligram potency is not precisely interchangeable—verify orders against the specific product labeling and pharmacy guidance.
Missed dose: Not specified in the reviewed prescribing information. For scheduled oral therapy, do not double doses; contact prescriber or pharmacist if multiple doses missed after abrupt high-dose therapy because withdrawal-type nausea, vomiting, dizziness, or tremulousness may occur—gradual taper per labeling.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Not specified in the reviewed prescribing information for oral onset timing | Hypotension and sedation may appear within 30 minutes to 2 hours after first oral dose—stay with patient |
| Peak | Not specified in the reviewed prescribing information | Reassess orthostatics and sedation after each new dose or formulation change |
| Duration | Not specified in the reviewed prescribing information | IM activity may last up to 12 hours in pediatric labeling context—verify interval on MAR |
| Half-life | Not specified in the reviewed prescribing information | Long-term therapy: periodic reassessment to use lowest effective maintenance dose |
On a small screen, swipe or scroll sideways to see the full table.
Titration
Increase dosage gradually until symptoms are controlled; debilitated, emaciated, and elderly patients need slower titration and closer observation. After control, reduce to the lowest effective maintenance dose and reassess periodically per labeling.
Before you give it — Safety check
Pretreatment checks
- Confirm indication is not dementia-related psychosis (boxed warning—drug not approved); review allergies to phenothiazines
- Obtain baseline orthostatic blood pressure and heart rate; assess fall risk, hydration, and concomitant antihypertensives or diuretics
- Screen for CNS depressants (opioids, alcohol, barbiturates), seizure disorder history, and CBC baseline if history of drug-induced leukopenia—monitor WBC early in therapy per labeling
Contraindications
- Known hypersensitivity to phenothiazines
- Comatose states or presence of large amounts of CNS depressants (alcohol, barbiturates, narcotics, etc.)
- Prior serious hypersensitivity or blood dyscrasias/jaundice with a phenothiazine unless prescriber judges benefit outweighs hazard
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| CNS depressants (opioids, alcohol, sedatives) | Additive sedation and respiratory depression; chlorpromazine prolongs and intensifies CNS depressant effects—about one-quarter to one-half usual sedative doses may be needed when combined | Monitor respiratory rate, sedation score, and ability to ambulate; hold or reduce concomitant sedatives per prescriber; stagger assessments after dose changes |
| Thiazide diuretics / antihypertensives | May accentuate orthostatic hypotension; may counteract guanethidine-related antihypertensive effect | Obtain orthostatics before and after early doses; teach slow position changes; notify prescriber if symptomatic hypotension |
| Lithium | Encephalopathic syndrome (weakness, fever, tremor, confusion, EPS, leukocytosis, elevated enzymes) reported—may resemble NMS and can progress to irreversible brain damage per labeling | Monitor neurologic status closely; discontinue promptly if toxicity signs appear; never assume agitation alone means more antipsychotic |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablets (including sugar-coated and film-coated products), oral concentrate, and IM/IV hydrochloride injection per institutional protocol and manufacturer labeling.
- Oral: may be given without regard to meals per common practice; use calibrated device for concentrates; swallow tablets whole unless pharmacy approves splitting/crushing for tube administration
- Injection: for acute severe symptoms, labeling recommends initial IM chlorpromazine then transition to oral when calm—verify correct mg vs mL and product concentration
- Do not mix IV push with incompatible agents; acetaminophen IV (Ofirmev) and diazepam are examples of physical incompatibility with other drugs—follow pharmacy compatibility checks for any co-administration
Postural hypotension, tachycardia, fainting, and dizziness may occur rarely after the first oral dose, usually recovering within 30 minutes to 2 hours but occasionally prolonged. Stay with the patient after initial doses, keep the bed low, call bell reachable, and do not allow unattended ambulation until orthostatic vitals are acceptable per protocol.
Expected therapeutic response
- Decreased agitation, psychotic symptoms, or nausea/vomiting without excessive sedation that prevents safe positioning or assessment
- Cooperative, calmer affect in acute psychosis or preoperative anxiety when titration is appropriate—full effect may take weeks in schizophrenia per labeling
- Hemodynamic stability with orthostatic BP and heart rate within prescriber/facility parameters after each dose change
Red flags — Stop and act
Treat sudden neurologic, hemodynamic, or hypersensitivity changes as urgent until proven otherwise. Chlorpromazine overdose is primarily supportive—no single antidote.
- Syncope, shock-like hypotension, or standing BP drop with dizziness after dosing—place head-low with legs raised; avoid epinephrine for pressor support per labeling
- Acute dystonia (neck spasm, tongue protrusion, swallowing difficulty) especially in younger males after dose increases
- Hyperpyrexia, muscle rigidity, altered mental status, autonomic instability suggesting neuroleptic malignant syndrome (NMS)
- Fever with grippe-like symptoms, dark urine, or jaundice—possible chlorpromazine-induced hepatotoxicity; stop drug and obtain hepatic studies
- Sore throat, fever, or infection signs with falling WBC—possible agranulocytosis; discontinue and obtain CBC per labeling
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Postural hypotension, tachycardia, dizziness | May occur rarely after first oral dose; occasionally prolonged or shock-like | Hold dose, head-low position, legs raised, orthostatic recheck; preferred pressors norepinephrine or phenylephrine—not epinephrine |
| Drowsiness / sedation | Common early in therapy, often decreases after 1–2 weeks | Fall precautions, supervise ambulation, avoid driving until cleared |
| Extrapyramidal symptoms | Dose-related: dystonia, akathisia, pseudo-parkinsonism, tardive dyskinesia | Assess movement disorders; treat acute EPS per protocol; report tardive movements early |
| Neuroleptic malignant syndrome | Rare; potentially fatal | Stop antipsychotic, supportive care, urgent escalation—do not mask with more sedatives |
| Jaundice / hepatotoxicity | Low overall incidence; usually reversible on withdrawal | Stop drug if fever with grippe-like symptoms and abnormal LFTs; avoid rechallenge if prior phenothiazine jaundice |
| Hematologic (agranulocytosis, leukopenia) | Serious but uncommon; often weeks 4–10 | Teach sore-throat reporting; obtain CBC if infection signs with cell decline |
| ECG changes | Nonspecific Q/T wave distortions reported | Obtain electrocardiogram when clinically indicated; compare to baseline |
| Anticholinergic effects | Dry mouth, constipation, urinary retention, blurred vision | Monitor hydration, bowel/bladder function; caution in Parkinson disease and glaucoma |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose primarily causes CNS depression (somnolence to coma) with hypotension and extrapyramidal symptoms. Agitation, restlessness, seizures, fever, ileus, and cardiac arrhythmias may occur per labeling.
Antidote
Not specified in the reviewed prescribing information — no single antidote. Treatment is symptomatic and supportive.
- Early gastric lavage may be helpful; maintain airway—severe EPS may cause dysphagia and respiratory difficulty
- Do not induce emesis—dystonic neck reactions risk aspiration
- EPS may be treated with antiparkinsonian drugs, barbiturates, or diphenhydramine per their prescribing information
- Hypotension: head-low position; vasoconstrictor if needed—norepinephrine or phenylephrine; epinephrine not recommended
- Avoid stimulants that lower seizure threshold (e.g., pentylenetetrazol); amphetamine or caffeine with sodium benzoate may be used if stimulation desired per labeling
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for overdose and polypharmacy ingestion.
Look-alike / sound-alike and error prevention
- Chlorpromazine vs prochlorperazine (Compazine) — both phenothiazines but different primary uses; verify indication (psychosis vs nausea)
- Chlorpromazine vs chlorpheniramine — antipsychotic vs antihistamine; LASA name confusion
- Thorazine brand legacy — confirm generic name on MAR and pump labels
- Tablet strength mix-ups — 10 mg vs 100 mg vs 200 mg; high strengths for severe conditions only
- MG vs mL in concentrates/injections — independent double-check with pharmacy
- IV physical incompatibility — never co-administer with incompatible agents (e.g., IV diazepam or Ofirmev per separate product labeling)
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Before first dose | Baseline orthostatics, fall score, and mental status; confirm indication documented |
| After dose | Remain available 30–120 minutes when possible; reassess BP and dizziness |
| Sun exposure | Photosensitivity reported—avoid undue sun; mild urticaria or severe TEN possible |
| Enteral tubes | Consult pharmacy for sugar-coated tablets and appropriate liquid formulation |
| Antiemetic masking | Do not dismiss new vomiting or nausea as controlled without assessing underlying cause |
| Ask pharmacy when | Lithium co-therapy, seizure threshold concerns, myelography timing (discontinue 48 h before metrizamide per labeling), or EPS treatment orders |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults / fall risk | Elderly patients are more susceptible to hypotension and neuromuscular reactions; use lower starting doses, slower titration, orthostatic monitoring, and recurrent fall-risk assessment per labeling. |
| Dementia-related psychosis | Boxed warning: increased mortality in elderly patients with dementia-related psychosis treated with antipsychotics—chlorpromazine is not approved for this use. Coordinate with the care team on non-pharmacologic and approved strategies for behavioral symptoms in dementia. |
| Hepatic, respiratory, and seizure disorders | Use cautiously with cirrhosis, severe asthma/COPD, and seizure disorders (may lower seizure threshold). Suppressed cough reflex increases aspiration risk if vomiting occurs. |
| Pregnancy | Safety in pregnancy has not been established—not recommended unless essential when benefits clearly outweigh hazards. Animal data show embryotoxicity; third-trimester exposure may cause neonatal EPS or withdrawal (agitation, hypertonia, hypotonia, tremor, respiratory distress, feeding disorder) per labeling. |
| Lactation | Excreted in breast milk; serious adverse reactions possible in nursing infants—decision should be made to discontinue nursing or the drug. LactMed (updated March 2025) notes detectable milk levels, possible infant drowsiness, cautious use possible with infant sedation and milestone monitoring; combination with haloperidol may affect development. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Orthostatic blood pressure and heart rate before and after first doses and titrations—use structured orthostatic blood pressure technique
- Level of consciousness, gait, extrapyramidal signs (restlessness, rigidity, involuntary movements), and temperature for NMS
- CBC during first months if low baseline WBC or prior drug-induced neutropenia; ECG if clinically indicated (nonspecific Q/T changes reported); hepatic panel if fever or jaundice
Document
- Dose, route, time, indication, orthostatic vital results, and patient response (sedation scale, behavior, nausea relief)
- EPS assessment after dose changes, fall precautions implemented, and prescriber/pharmacist notifications for hypotension or neurologic events
- Patient teaching on slow position changes, avoiding alcohol, and when to report fever, rigid muscles, yellowing skin, or sore throat
Patient teaching
- Stand up slowly from sitting or lying—dizziness or fainting can occur, especially after the first doses
- Avoid alcohol and do not take extra sedating medicines unless prescribed—chlorpromazine adds to drowsiness and impaired alertness
- Report fever, stiff muscles, confusion, yellow skin or eyes, sore throat, or uncontrollable body or mouth movements immediately
- Use fall precautions at home: cleared pathways, adequate lighting, non-slip footwear, assistance with ambulation when sedated
- Do not stop high-dose therapy suddenly without prescriber guidance—withdrawal-type nausea, vomiting, dizziness, or tremulousness may occur after abrupt discontinuation per labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Symptomatic postural hypotension, syncope, or prescriber-defined unacceptable orthostatic drop after dosing
- Suspected NMS (hyperpyrexia, rigidity, altered mental status, autonomic instability) or acute severe dystonia with airway concern
- Known phenothiazine hypersensitivity, comatose state, or excessive concurrent CNS depression
- Fever with infection signs plus declining WBC/neutrophils, or new jaundice/hepatitis picture
- Order is for dementia-related psychosis without approved exception—drug is not indicated; escalate to prescriber per boxed warning policy
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Chlorpromazine is sedating and hemodynamically active—calm behavior after a dose does not prove safety. Build orthostatic checks and EPS screening into each medication administration pass the same way you would for opioids or vasodilators.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and indication aligns with approved use (not dementia-related psychosis)
- Review orthostatic vitals, recent sedatives/alcohol, diuretics, and antihypertensives
- Assess for EPS, fever, or infection since last dose; confirm fall precautions and supervision plan for ambulation
- Verify LASA product (chlorpromazine vs prochlorperazine) and correct oral strength (10–200 mg tablets are not interchangeable)
2. High-alert and safety badge
Not a universal high-alert drug—treat first doses like high-risk hemodynamic therapyAlthough not on all institutional high-alert lists, chlorpromazine’s first-dose hypotension, EPS, NMS, and fall-risk profile warrant independent double-checks on initiation, titration, and route changes—especially in older adults.
3. Clinical workflow: hold and question rules
- If dizziness or BP drop follows a dose, hold the next dose, reposition safely, recheck orthostatics, and call prescriber/pharmacist before continuing titration
- If agitation worsens with motor restlessness, consider akathisia or EPS rather than automatically escalating antipsychotic dose
- For suspected overdose, maintain airway, avoid emesis induction (dystonia/aspiration risk), support blood pressure with recommended vasopressors only, and contact poison control or toxicology per facility protocol
4. Critical teach-back questions
- “What should you do when you stand up after taking chlorpromazine?” (Patient should say stand up slowly, sit back down if dizzy, and report fainting or falls—matching orthostatic teaching.)
- “Which symptoms mean you need urgent medical review?” (High fever with rigid muscles, confusion, yellow skin/eyes, severe sore throat, or new uncontrollable movements.)
5. Care coordination
Pharmacist: Dose titration in elderly or hepatic impairment, interaction review (lithium, diuretics, anticonvulsants), EPS treatment selection, and compatibility checks for injectable products
Prescriber / mental health: Notify for persistent hypotension, NMS features, blood dyscrasias, hepatotoxicity, or need to switch antipsychotic when tardive dyskinesia appears
🧠 Quick mental checklist
- When is the next orthostatic blood pressure check due—especially after first doses?
- Does this patient have dementia-related psychosis (boxed warning) or legitimate acute indication?
- Any dystonia, restlessness, rigidity, fever, or autonomic changes since the last dose?
- Are diuretics, antihypertensives, lithium, or sedatives amplifying risk?
- If hypotension occurs, will I avoid epinephrine and use positioning plus norepinephrine or phenylephrine per prescriber?
Chlorpromazine NCLEX practice questions
Practice NCLEX-style clinical judgment practice for chlorpromazine with a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, orthostatic trend interpretation, matrix urgency sorting, NMS versus EPS judgment, and vasopressor cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Chlorpromazine 25 mg PO at 0800 (first inpatient dose)
- Scheduled repeat: chlorpromazine 25 mg PO q8h — due 1600
- PRN lorazepam 0.5 mg PO — not given
- Home med list: thiazide diuretic continued per prescriber
- Admission CBC: WBC 6.8 ×10⁹/L; baseline for antipsychotic monitoring
- BMP: within reference range
- No hepatic panel drawn yet — monitor if fever or jaundice develops
- Pre-dose 0745: BP 128/76 mmHg sitting; HR 88/min
- 0830 (after 0800 dose): BP 98/58 mmHg sitting; HR 104/min; patient dizzy
- 0845 orthostatics: lying 102/60 → standing 82/48; reports lightheadedness
- 78-year-old with acute agitation on a medical unit; no dementia-related psychosis order
- 0900: Mild neck stiffness noted; patient able to swallow water
- 0915: Fall-risk bracelet in place; bed in low position; call bell within reach
- 0920: Nurse preparing to give 1600 dose while patient still symptomatically hypotensive
Answer key & rationale
Frequently asked questions
Why is orthostatic blood pressure monitoring important with chlorpromazine?
Labeling states postural hypotension, tachycardia, fainting, and dizziness may occur rarely after the first oral dose, sometimes becoming severe or prolonged. Nurses should obtain orthostatic vitals around initiation and titration, use head-low positioning with legs raised for hypotension, and avoid epinephrine if a vasoconstrictor is needed—norepinephrine or phenylephrine are preferred.
When should a nurse hold chlorpromazine?
Hold for symptomatic hypotension or syncope, suspected NMS, acute severe dystonia, phenothiazine hypersensitivity, excessive CNS depression, fever with falling white blood cell count, new jaundice, or orders for unapproved dementia-related psychosis. Contact the prescriber or pharmacist before redosing.
What extrapyramidal reactions should nurses watch for?
Dose-related EPS include dystonia (especially early, higher risk in males and younger patients), motor restlessness, pseudo-parkinsonism, and tardive dyskinesia. Acute dystonia may require antiparkinsonian agents such as diphenhydramine per protocol. Tardive dyskinesia may be irreversible—report involuntary oral-facial movements early.
Is there an antidote for chlorpromazine overdose?
No specific antidote is listed. Overdose treatment is symptomatic and supportive: airway management, avoid emesis induction because of dystonic aspiration risk, treat EPS with diphenhydramine or antiparkinsonian drugs per labeling, and support hypotension with positioning and norepinephrine or phenylephrine—not epinephrine. Contact poison control or toxicology per facility protocol.
Can chlorpromazine be used in dementia-related psychosis?
No. A boxed warning states elderly patients with dementia-related psychosis treated with antipsychotics have increased mortality, and chlorpromazine is not approved for that indication. Use facility protocols for behavioral symptoms in dementia and non-pharmacologic measures first when appropriate.
References
-
U.S. National Library of Medicine. Chlorpromazine hydrochloride tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2a8b8a3-187f-4000-bde3-b40bb0e5600f
-
Drugs and Lactation Database (LactMed). Chlorpromazine. Bethesda (MD): National Institute of Child Health and Human Development; updated March 15, 2025.https://www.ncbi.nlm.nih.gov/books/NBK501540/
-
Drugs and Lactation Database (LactMed). Antipsychotic drugs and breastfeeding. In: Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK253300/
-
U.S. Food and Drug Administration. Antipsychotic drug labels updated on altered warning regarding use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-antipsychotic-drug-labels-updated-altered-warning
-
U.S. National Library of Medicine. Chlorpromazine hydrochloride injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=509938d5-2658-4840-96ef-d1d892fcdab9
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.